Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00213993 · ClinicalTrials.gov registry record · Phase 2
Topical Antiperspirant for Hand-Foot Syndrome
A Phase 2 study of Palmar-plantar Erythrodysesthesia, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT00213993: Completed Phase 2 study of Palmar-plantar Erythrodysesthesia, sponsored by University of Wisconsin, Madison.
NCT00213993 is a Phase 2 study of Palmar-plantar Erythrodysesthesia that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 14 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00213993, a Phase 2 study of Palmar-plantar Erythrodysesthesia, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
The objectives of this study are to evaluate the effectiveness of an antiperspirant in preventing or attenuating the severity of palmer-plantar erythrodysesthesia associated with the Food and Drug Administration (FDA)-approved doses of capecitabine. The hypothesis is that cytotoxic compounds in sweat will be prevented from being deposited in the skin and causing chronic toxicity.
Conditions Studied
Interventions
- DRUG antiperspirant
Study Locations (1)
Wisconsin
- University of Wisconsin - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2005-05 |
| Est. Completion | 2007-01 |
| Phase | Phase 2 |
What the finished NCT00213993 record still lists
NCT00213993 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Palmar-plantar Erythrodysesthesia appearing as the primary indexed condition, and to 1 intervention - of which antiperspirant is the first listed.
NCT00213993 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT00213993 about?
NCT00213993 is a clinical study titled "Topical Antiperspirant for Hand-Foot Syndrome". The objectives of this study are to evaluate the effectiveness of an antiperspirant in preventing or attenuating the severity of palmer-plantar erythrodysesthesia associated with the Food and Drug Administration (FDA)-approved doses of capecitabine. The hypothesis is that cytotoxic compounds in swea...
What is the current status of trial NCT00213993?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2005-05. Estimated completion is 2007-01.
What conditions does trial NCT00213993 study?
This clinical trial studies the following conditions: Palmar-plantar Erythrodysesthesia.
What interventions are being tested in trial NCT00213993?
The interventions under investigation include: antiperspirant (DRUG).
Who is sponsoring clinical trial NCT00213993?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00213993 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Palmar-plantar Erythrodysesthesia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00213993's enrollment target sits among peer trials
14 1941st of 2000 higher than 54 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia